Germany - Pharmaceuticals

Description

This notice does not concern the award of a public contract within the meaning of the Public Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedure description "open procedure" (Section IV.1.1) used in this announcement is due to the requirements of the announcement form. This and the use of the "TED" medium are not associated with any submission to public procurement regulations, the application of which is not mandatory by law or public procurement regulations. This is a framework agreement with an option to join, which relates to various active ingredients.
The subject of the agreement are medicinal products containing the active ingredient combination beclometasone dipropionate and formoterol in the dosage form metered dose inhaler and in the strength 100/6 micrograms. The subject of the contract are medicinal products containing the active substance combination beclometasone dipropionate and formoterol in the dosage form metered dose inhaler and in the strength 200/6 micrograms. The subject of the contract are medicinal products containing the active substance combination beclometasone dipropionate and formoterol in the pharmaceutical form inhalation powder and in the strength 100/6 micrograms. The subject of the contract are medicinal products containing the active substance combination beclometasone dipropionate and formoterol in the pharmaceutical form inhalation powder and in the strength 200/6 micrograms. The subject of the contract are medicinal products containing the active ingredient combination beclometasone dipropionate and formoterol in the pharmaceutical form inhalation powder. The subject of the contract are medicinal products containing the active substance budesonide in the dosage form metered dose inhaler. The subject of the contract are medicinal products containing the active substance ciclosporin in an ophthalmic dosage form in single-dose pipettes. The subject of the contract are medicinal products containing the active ingredient clonazepam. The subject of the contract are medicinal products containing the active ingredient dalteparin sodium. The contract covers medicinal products containing the active ingredient eletriptan. The contract covers medicinal products containing the active ingredient enoxaparin sodium in the standard size N2 and potency 100mg. The contract covers medicinal products containing the active ingredient epoetin beta. The contract covers medicinal products containing the active ingredient epoetin zeta. The subject of the contract are medicinal products containing the active ingredient follitropin beta. The contract covers medicinal products containing the active substance goserelin. The subject matter of the contract is medicinal products containing the active substance granisetron in the pharmaceutical form ILO. The subject of the contract are medicinal products containing the active ingredient granisetron in the transdermal patch dosage form. The subject of the contract are medicinal products containing the active substance human immunoglobulin G. The contract covers medicinal products containing the active substance interferon beta-1a (Avonex®). The subject of the contract are medicinal products containing the active substance natalizumab in an intravascular dosage form. The subject matter of the contract is medicinal products containing the active substance natalizumab in a subcutaneous dosage form. The subject of the contract are medicinal products containing the active substance paliperidone in the dosage form DIS. The subject of the contract are medicinal products containing the active substance testosterone. The subject of the contract are medicinal products containing the active substance tinzaparin sodium. The subject of the contract are medicinal products containing the active substance tobramycin in the pharmaceutical form hard capsule with powder for inhalation. The contract covers medicinal products containing the active ingredient tocilizumab in an intravenous dosage form. The subject matter of the contract is medicinal products containing the active ingredient tocilizumab in a subcutaneous dosage form. The contract covers medicinal products containing the active substance triamcinolone acetonide with the ATC code D07AB09. The contract covers medicinal products containing the active substance trientine.

Opportunity closing date

01 November 2025

Value of contract

£0-100k